Greece
3.0researchedA state-funded scheme covering 43,500 patients with BMI 37 and very high cardiovascular risk, whose EU funding collapsed mid-2026 and is being moved onto the state budget. Ownership was tightened in May 2026, and no pan-EU telehealth brand serves Greece at all.
- Population
- 10.4m
- Currency
- EUR
- Region
- South-eastern Europe
- Updated
- 2026-08-24
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
Ownership tightened in May 2026 [1][2]
Since 2018 Greek law permitted non-pharmacists and investment firms to acquire up to 99.99% of a pharmacy, described in Greek reporting as a loophole that let pharmacists become effectively employees in their own licensed premises and that drew private-equity interest.
A May 2026 omnibus bill requires pharmacists to retain a minimum 33% stake, explicitly aimed at discouraging pure investment-fund ownership, since 33% gives the pharmacist a blocking position. Investors may still hold up to 67%. The pharmacists’ association wants pharmacist-majority ownership matching France and Spain; that is not law.
Any model premised on majority external control of a Greek pharmacy has to account for the new floor.
The scheme: who qualifies, and what went wrong [1][2][3]
The programme targets adults with BMI 37 or above combined with very high cardiovascular risk, identified through a cardiovascular screening process, with pharmaceutical treatment plus medical and dietary monitoring. 43,500 beneficiaries were enrolled, some mid-course on an eight-dose regimen.
What happened in mid-2026 is more specific than a Mounjaro stoppage. The European Commission’s Recovery and Resilience Facility review reclassified the programme’s expense as a recurring cost rather than a one-off investment, disqualifying it from continued RRF financing. That created a funding gap for the existing cohort and left pharmacies unpaid for May and June 2026 dispensing, which the pharmacists’ union raised directly at a 22 July meeting with the health ministry.
The deputy health minister promised normalisation within fifteen days on 16 July 2026 and confirmed on 20 July that the programme would continue, funded from the state budget from September 2026, with outstanding pharmacy debts settled within two to three weeks of a legislative amendment. No source dated after 22 July 2026 confirms normal prescribing has resumed.
Nobody is selling here [1]
This is the most commercially telling finding. None of ZAVA, DoktorABC or euroClinix maintains a Greek storefront. euroClinix’s own country list covers England, Sweden, Portugal, Germany, Denmark, Switzerland, Finland, France and Norway, and excludes Greece exactly as it excludes Belgium. No domestic Greek GLP-1 telehealth operator could be identified either.
That is suggestive rather than conclusive, but the pattern matches Belgium, the other market in this atlas where mail order is closed and the pan-EU brands stay away.
Advertising and enforcement [1][2]
EOF’s legal basis is KYA Δ.ΥΓ3α/Γ.Π. 32221/2013 article 130, which requires pharmaceutical companies to submit promotional and informational material for both professional and public-facing content, via separate forms since 31 May 2021.
No GLP-1-specific enforcement was found. EOF and the Panhellenic Pharmaceutical Association did act jointly on 10 August 2026 against illegal marketing of intravenous therapies falsely presented as dietary supplements, warning that these are not legitimate supplements and pose a public-health risk. That is not GLP-1 advertising, but it shows an active posture against weight and wellness product misrepresentation.
Who is already there
| Name | Model | Price |
|---|---|---|
| State scheme via EOPYY | BMI 37 plus very high cardiovascular risk, state and formerly EU-funded, with in-person medical and dietary monitoring | Free to 43,500 enrolled beneficiaries; funding moved to the state budget from September 2026 |
| ZAVA, DoktorABC, euroClinix | Pan-EU telehealth brands checked. None lists Greece as a served market | n/a |
| No domestic operator identified | No Greek DTC GLP-1 telehealth operator was found in this pass | n/a |
Routes in, and walls
What works viable
- Targeting the population excluded from the state scheme, which is most of the overweight population given the BMI 37 plus cardiovascular-risk gate.
- Note that no pan-EU brand is present. That is either a real opening or a signal worth understanding before spending anything.
What does not blocked
- A model premised on majority external control of a Greek pharmacy without accounting for the May 2026 33% floor.
- Assuming Rx mail order is available. Nothing confirms it either way, and the absence of every major operator is not encouraging.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Target the population excluded by the BMI 37 plus cardiovascular-risk gate, and first work out why no pan-EU brand is here.
The state scheme gate is high enough that most of the overweight population is excluded, which is a large self-pay opening. But no pan-European brand has entered, and that is either a real opportunity or a signal about something not visible from outside. Find out which before spending.
- Establish why no pan-EU operator is presentThis is the first question, not the last. It is cheap to answer and it changes everything.
- If the answer is benign, target the sub-37 BMI populationThe gate excludes most of the market.
- Plan for collection rather than deliveryMail order scores 2 out of 5.
The unexplained absence of every pan-European operator. Assume it is informative until proven otherwise.
Do the diagnostic first. It is a week of work.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- Was the funding disruption actually resolved? The last confirmed status is from 22 July 2026.
- What is the total obese adult population, needed to size the share excluded from the scheme?
- What is the primary legal text on Rx mail order and internet pharmacy sales in Greece?
- Is any operator, domestic or foreign, actively serving Greek GLP-1 patients, and at what price?
- Has the May 2026 omnibus bill with the 33% pharmacist stake passed into force, and what is its exact text?
On the shared backlog: What are the eligibility criteria for Greece's free GLP-1 obesity scheme?
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.